| __timestamp | Eli Lilly and Company | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 72429000 |
| Thursday, January 1, 2015 | 6533000000 | 78634000 |
| Friday, January 1, 2016 | 6452000000 | 75374000 |
| Sunday, January 1, 2017 | 6588100000 | 92157000 |
| Monday, January 1, 2018 | 5975100000 | 93326000 |
| Tuesday, January 1, 2019 | 6213800000 | 103132000 |
| Wednesday, January 1, 2020 | 6121200000 | 110171000 |
| Friday, January 1, 2021 | 6431600000 | 218817000 |
| Saturday, January 1, 2022 | 6440400000 | 233827000 |
| Sunday, January 1, 2023 | 6941200000 | 267194000 |
| Monday, January 1, 2024 | 8593800000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Eli Lilly and Company and Lantheus Holdings, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Eli Lilly, a titan in the industry, consistently reported SG&A expenses averaging around $6.4 billion annually. In contrast, Lantheus Holdings, a smaller player, maintained a leaner approach with expenses averaging approximately $134 million per year.
From 2014 to 2023, Eli Lilly's SG&A expenses saw a modest increase of about 5%, peaking in 2023. Meanwhile, Lantheus Holdings experienced a significant surge, with expenses growing by over 270% during the same period. This divergence highlights the differing scales and operational strategies of these companies. As the pharmaceutical industry continues to innovate, understanding these financial dynamics offers valuable insights into corporate strategy and market positioning.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Breaking Down Revenue Trends: Eli Lilly and Company vs Lantheus Holdings, Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Lantheus Holdings, Inc.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Perrigo Company plc
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc. Trends and Insights